您的购物车当前为空
别名 N6-[2-(4-氨基苯基)乙基]腺嘌呤, N6-[2-(4-Aminophenyl)ethyl]adenosine, (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) 是腺苷 A3 受体的非选择性激动剂。

APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) 是腺苷 A3 受体的非选择性激动剂。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 mg | ¥ 153 | 现货 | |
| 10 mg | ¥ 215 | 现货 | |
| 25 mg | ¥ 349 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 193 | 现货 |
APNEA 相关产品
| 产品描述 | APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) is a non-selective agonist of adenosine A3 receptor. |
| 体外活性 | APNEA在1 mg/kg的次预防剂量下,针对电休克显著增强了苯巴比妥、苯妥英钠和丙戊酸钠对最大电休克的抗惊厥作用,而在更低剂量时则无效[2]。 |
| 体内活性 | APNEA(0.0039-1 mg/kg)提高了卡马西平的保护效果。无论是单独使用或与卡马西平联合应用,APNEA(0.0156和1 mg/kg)显著降低了体温,并损害了长期记忆[2]。 |
| 别名 | N6-[2-(4-氨基苯基)乙基]腺嘌呤, N6-[2-(4-Aminophenyl)ethyl]adenosine, (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol |
| 分子量 | 386.41 |
| 分子式 | C18H22N6O4 |
| CAS No. | 89705-21-5 |
| Smiles | Nc1ccc(CCNc2ncnc3n(cnc23)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)cc1 |
| 密度 | 1.65 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 200 mg/mL (517.58 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (12.94 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容